The markets opened modestly higher with the Dow adding 7 points to 12,774 after Greek voters chose to stay in the euro. Nasdaq climbed 17 points to 2890.
On the upside
Morgan Stanley analyst Scott Devitt upgraded Groupon (Nasdaq: GRPN) to an overweight rating.
According to TheStreet’s FDA Drug Approval Contest, Arena Pharmaceuticals’ (Nasdaq: ARNA) Lorcaserin is expected to receive regulatory approval on June 27.
Bargain hunters lifted shares of A123 Systems (Nasdaq: AONE).
On the downside
Body Central (Nasdaq: BODY) cut its second quarter and full year earnings and revenue outlook due to weak sales.
DSW (NYSE: DSW) cut its second quarter outlook.
The Food and Drug Administration affirmed its approval for K-V Pharmaceutical’s (NYSE: KVA) preterm birth treatment Makena.
In the broad market, advancing issues outpaced decliners by a margin of nearly 10 to 9 on the NYSE while decliners edged out advancers by 10 to 9 on Nasdaq. The Russell 2000 which tracks small cap stocks climbed held steady at 771.